Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (nerati
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells - ScienceDirect
Alison Dent - Senior Clinical Specialist - Breast Cancer - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Cana
Find a Job | Puma Biotechnology, Inc.
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
Articles about Puma Biotechnology
Puma Biotechnology Alisertib , an Aurora Kinase A Inhibitor
Puma Biotechnology's Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NE
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
PUMA mediates therapeutic responses to sunitinib in vivo. (A) Left,... | Download Scientific Diagram
Puma Biotechnology
Puma Biotechnology
RETRACTED ARTICLE: Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway | Cancer Gene Therapy
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio - TheStreet
